The CTU co-ordinates broad portfolio of phase I, II and III clinical trials, with an emphasis on translational research. For example, we have been at the forefront of a major program of national and international studies in ovarian cancer through the Scottish Gynaecological Cancer Trials Group, which is linking prospective tumour and blood sample collection with clinical outcome data for molecular studies. This work continues in a new generation of SGCTG studies and other translational studies initiated by local investigators.

The CTU maintains strong productive links with the Beatson Institute. These links are aimed at two main areas of research:

  1. The identification and assessment of molecular markers in the context of clinical trials aimed at a more rationally directed drug development and tailored treatment based on molecular pathology.
  2. The rapid advancement of novel anti-cancer therapeutics from the laboratory into the clinic to test their promise in early clinical trials. The Trials Units close links with the Clinical Research Unit are fundamental here.

Jointly with the Beatson Institute we have been awarded Experimental Cancer Medicine centre status br Cancer Research UK. This is recognition of our scientific and clinical excellence in translational research. More information about this can be found at: Glasgow ECMC.